| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 15, 2005
From the Department of Biochemistry, Ohio University, Athens, Ohio (L.K., A.M.J., T.M.); Elucida Research, Beverly, Mass (R.P.M., R.F.J.); and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (R.P.M.). Dr Kalinowski was on sabbatical leave from the University of Gdansk. * To whom correspondence should be addressed. E-mail: malinski{at}ohiou.edu.
Background--Alterations in endothelial function may contribute to increased susceptibility of black Americans to cardiovascular disease. The ability to pharmacologically reverse endothelial dysfunction in blacks was tested with nebivolol, a Methods and Results--The effects of nebivolol on endothelial nitric oxide (NO), superoxide (O2-), and peroxynitrite concentration (ONOO-) release were studied in human umbilical vein endothelial cells and iliac artery endothelial cells isolated from age-matched black and white donors. Kinetics and concentrations of NO/O2-/ONOO- were measured simultaneously with nanosensors from single cells and shown to have significant interracial differences. The rate of NO release was Conclusions--Reduced endothelial NO bioavailability in American blacks is mainly due to excessive O2- and ONOO- generation by NAD(P)H and uncoupled endothelial NO synthase. Nebivolol decreased O2- and ONOO- concentrations and restored NO bioavailability in blacks to the level recorded in cells from whites, independently of
Revised on August 8, 2005
Accepted on September 19, 2005
Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans
R. Preston Mason PhD,
1-selective agent with vasodilating and antioxidant properties.
5 times slower in blacks than in whites (94 versus 505 nmol · L-1 · s-1), whereas the rates of release were faster by
2 times for O2- and
4 times for ONOO- (22.1 versus 9.4 nmol · L-1 · s-1 for O2- and 810 versus 209 nmol · L-1 · s-1 for ONOO-). Pretreatment with 1.0 to 5.0 µmol/L nebivolol restored NO bioavailability in endothelial cells from black donors with concurrent reductions in O2- and ONOO- release, similar to levels in the endothelium of whites. The effects of nebivolol were dose-dependent and not observed with atenolol; similar effects were observed with apocynin, an NAD(P)H oxidase inhibitor.
1-selective blockade.
This article has been cited by other articles:
![]() |
E. Osto, C. M. Matter, A. Kouroedov, T. Malinski, M. Bachschmid, G. G. Camici, U. Kilic, T. Stallmach, J. Boren, S. Iliceto, et al. c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress Circulation, November 11, 2008; 118(20): 2073 - 2080. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hallstrom, M. Franz, H. Gasser, M. Vodrazka, S. Semsroth, U. M. Losert, M. Haisjackl, B. K. Podesser, and T. Malinski S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart after unprotected warm ischaemia Cardiovasc Res, February 1, 2008; 77(3): 506 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Mata-Greenwood and D.-B. Chen Racial Differences in Nitric Oxide--Dependent Vasorelaxation Reproductive Sciences, January 1, 2008; 15(1): 9 - 25. [Abstract] [PDF] |
||||
![]() |
G. Peluffo and R. Radi Biochemistry of protein tyrosine nitration in cardiovascular pathology Cardiovasc Res, July 15, 2007; 75(2): 291 - 302. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |